0001104659-23-006545.txt : 20230125
0001104659-23-006545.hdr.sgml : 20230125
20230125161640
ACCESSION NUMBER: 0001104659-23-006545
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230120
FILED AS OF DATE: 20230125
DATE AS OF CHANGE: 20230125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bradley Greg
CENTRAL INDEX KEY: 0001833504
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39752
FILM NUMBER: 23552660
MAIL ADDRESS:
STREET 1: 200 U.S. 9
STREET 2: SUITE 500
CITY: MANALAPAN TOWNSHIP
STATE: NJ
ZIP: 07726
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Petros Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001815903
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851410058
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 973-242-0005
MAIL ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
4
1
tm234334-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-01-20
0
0001815903
Petros Pharmaceuticals, Inc.
PTPI
0001833504
Bradley Greg
C/O PETROS PHARMACEUTICALS, INC.
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Common Stock
2023-01-20
4
M
0
2264
A
2264
D
Restricted Stock Units
2023-01-20
4
M
0
2264
0
D
Common Stock
2264
0
D
On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split.
On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023.
Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer.
/s/ Mitchell Arnold, attorney-in-fact
2023-01-25